Loading...
•
Jun 30, 2020
Cerus Q2 2020 Earnings Report
Cerus's Q2 2020 results were announced, featuring record quarterly product revenue and progress in development programs.
Key Takeaways
Cerus Corporation announced record second-quarter results, with total revenue reaching $26.8 million. Product revenue was $21.5 million, driven by strong platelet kit sales in the U.S. and plasma and illuminator sales in EMEA. The company reaffirmed its full-year product revenue guidance of $89 million to $93 million.
Total revenue reached $26.8 million, a 19.1% increase year-over-year.
Product revenue hit a record $21.5 million, driven by platelet kit sales in the U.S. and plasma and illuminator sales in EMEA.
Reaffirmed 2020 full-year product revenue guidance of $89 million to $93 million.
Submitted a pre-market approval supplement to the FDA for pathogen-reduced cryoprecipitated fibrinogen complex.
Cerus
Cerus
Cerus Revenue by Segment
Cerus Revenue by Geographic Location
Revenue by Segment
Product Revenue
CapyFin.comGovernment Contract Revenue
CapyFin.comRevenue by Geographic Location
North America Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
The Company expects 2020 product revenue to be in the range of $89 million to $93 million, unchanged from the guidance originally provided on January 13, 2020. The guidance range represents approximately 20% to 25% growth compared to 2019 reported product revenue.